Abuse and Therapeutic Use of Benzodiazepines and Benzodiazepine-Like Drugs

James H. Woods, Jonathan L. Katz, and Gail Winger


1. Adam K, Oswald I. Can a rapidly-eliminated hypnotic cause daytime anxiety? Pharmacopsychiatry 1989;22:115–119.

2. Agnoli A, Manna V, Martucci N. Double-blind study on the hypnotic and antianxiety effects of zopiclone compared with nitrazepam in the treatment of insomnia. Int J Clin Pharmacol Res 1989;9: 277–281.

3. Ballenger JC, McDonald S, Noyes R Jr, et al. The first double-blind, placebo-controlled trial of a partial benzodiazepine agonist, abecarnil (ZK 112-119), in generalized anxiety disorder. Adv Biochem Psychopharmacol 1992;47:431–447.

4. Balter MB, Levine J, Manheimer DI. Cross-national study of the extent of anti-anxiety/sedative drug use. N Engl J Med 1974; 290:769–774.

5. Balter MB. Benzodiazepine use/abuse: an epidemiologic appraisal. Presented at symposium, Triplicate Prescription: Issues and Answers, New York, February 28, 1991.

6. Bechelli LPDC, Navas F, Pierangelo SA. Comparison of the reinforcing properties of zopiclone and triazolam in former alcoholics. Pharmacology 1983;27(Suppl 2):235–241.

7. Bensimon G, Foret J, Warot D, Lacomblez L, Thiercelin JF, Simon P. Daytime wakefulness following a bedtime oral dose of zolpidem 20 mg, flunitrazepam 2 mg and placebo. Br J Clin Pharmacol 1990;30(3):463–469.

8. Benzodiazepine/Driving Collaborative Group. Are benzodiazepines a risk factor for road accidents? Drug Alcohol Depend 1993;33: 19–22.

9. Bianchi M, Musch B. Zopiclone discontinuation: review of 25 studies assessing withdrawal and rebound phenomena. Int Clin Psychopharmacol 1990;5(Suppl 2):139–145.

10. Billiard M, Besset A, de Lustrac C, Brissaud L, Cadilhac J. Effects of zopiclone on sleep, daytime somnolence and nocturnal and daytime performance in healthy volunteers. Neurophysiol Clin 1989;19(2):131–143.

11. Bliwise DL, Seidel WF, Cohen SA, Bliwise NG, Dement WC. Profile of mood states changes during and after 5 weeks of nightly triazolam administration. J Clin Psychiatry 1988;49:349–355.

12. Boisse NR, Quaglietta N, Samoriski GM, Guarini JJ. Tolerance and physical dependence to a short-acting benzodiazepine, midazolam. J Pharmacol Exp Ther 1990;252:1125–1133.

13. Broadhurst A, Cushnaghan RC. Residual effects of zopiclone (Imovane). Sleep 1987;10(Suppl 1):48–53.

14. Cashman JN, Power SJ, Jones RM. Assessment of a new hypnotic imidazo-pyridine (zolpidem) as oral premedication. Br J Clin Pharmacol 1987;24:85–92.

15. Declerck AC, Ruwe F, O'Hanlon JF, Wauquier A. Effects of zolpidem and flunitrazepam on nocturnal sleep of women subjectively complaining of insomnia. Psychopharmacology (Berl) 1992; 106:497–501.

16. De Wit H, Pierri J, Johanson C-E. Reinforcing and subjective effects of diazepam in nondrug-abusing volunteers. Pharmacol Biochem Behav 1989;33:205–213.

17. Duka T, Schütt B, Krause W, Dorow R, McDonald S, Fichte K. Human studies on abecarnil a new b-carboline anxiolytic: safety, tolerability and preliminary pharmacological profile. Br J Clin Pharmacol 1993;35:386–394.

18. Eddy N, Isbell H. Public Health Rep 1959;74:755–763.

19. Evans SM, Funderburk FR, Griffiths RR. Zolpidem and triazolam in humans: behavioral and subjective effects and abuse liability. J Pharmacol Exp Ther 1990;255(3):1246–1255.

20. Falk JL, Tang M. Development of physical dependence on midazolam by oral self-administration. Pharmacol Biochem Behav 1987;26:797–800.

21. Fontaine R, Beaudry P, Le Morvan P, Beauclair L, Chouinard G. Zopiclone and triazolam in insomnia associated with generalized anxiety disorder: a placebo-controlled evaluation of efficacy and daytime anxiety. Int Clin Psychopharmacol 1990;5:173–183.

22. Fraser HF, Wikler A, Essig CF, Isbell H. Degree of physical dependence induced by secobarbital or pentobarbital. JAMA 1958; 166:126–129.

23. Frattola L, Maggioni M, Cesana B, Priore P. Double blind comparison of zolpidem 20 mg versus flunitrazepam 2 mg in insomniac in-patients. Drugs Exp Clin Res 1990;16:371–376.

24. Gallager DW, Heninger K, Heninger G. Periodic benzodiazepine antagonist administration prevents benzodiazepine withdrawal symptoms in primates. Eur J Pharmacol 1986;132:31–38.

25. Gorenstein C, Tavares SM, Gentil V, Peres C, Moreno RA, Dreyfus JF. Psychophysiological effects and dose equivalence of zopiclone and triazolam administered to healthy volunteers: methodological considerations. Braz J Med Biol Res 1990;23(10):941–951.

26. Greenblatt DJ, Shader RI, Abernethy DR. Drug therapy: current status of benzodiazepines. N Engl J Med 1983;309:354–358.

27. Greenblatt DJ, Shader RI, Harmatz JS. Implications of altered drug disposition in the elderly: studies of benzodiazepines. J Clin Pharmacol 1989;29:866–872.

28. Griffiths RR, Sannerud CA, Ator NA, Brady JV. Zolpidem behavioral pharmacology in baboons: self-injection, discrimination, tolerance and withdrawal. J Pharmacol Exp Ther 1992;260:1199–1208.

29. Haefely WE. Pharmacology of the benzodiazepine receptor. Eur Arch Psychiatry Neurol Sci 1989;238:294–301.

30. Haefely WE. Pharmacology of the allosteric modulation of GABAa receptors by benzodiazepine receptor ligands. In: Barnard EA, Costa E, eds. Allosteric modulation of amino acid receptors: therapeutic implications. New York: Raven Press, 1989;47–69.

31. Haefely WE. The GABA–benzodiazepine interaction fifteen years later. Neurochem Res 1990;15:169–174.

32. Hindmarch I. Immediate and overnight effects of zopiclone 7.5 mg and nitrazepam 5 mg with ethanol, on psychomotor performance and memory in healthy volunteers. Int Clin Psychopharmacol 1990;5(Suppl 2):105–113.

33. Hollister LE, Motzenbecker FP, Degan RO. Withdrawal reactions from chlordiazepoxide ("Librium"). Psychopharmacologia 1961; 2:63–68.

34. Hollister LE. Dependence on benzodiazepines. In: Szara I, Ludford JP, eds. Benzodiazepines: a review of research results, 1980. NIDA research monograph series 33. Washington, DC: U.S. Government Printing Office, 1981;70–82.

35. Hollister LE, Müller-Oerlinghausen B, Rickels K, Shader RI. Clinical uses of benzodiazepines. J Clin Psychopharmacol 1993; 13(Suppl 1):1S–169S.

36. Johnston LD, O'Malley PM, Bachman JG. National survey results on drug use from the "monitoring the future" study, 1975–1992, vol I: Secondary school students. NIH publication no. 93-3597. Washington, DC: U.S. Government Printing Office, 1993.

37. Johnston LD, O'Malley PM, Bachman JG. National survey results on drug use from the "monitoring the future" study, 1975–1992, volume II: College students and young adults. NIH publication no. 93-3598. Washington, DC: U.S. Government Printing Office, 1993.

38. Kales A, Soldatos CR, Bixler EO, Kales JD. Early morning insomnia with rapidly eliminated benzodiazepines. Science 1983;220:95–97.

39. Kryger MH, Steljes D, Pouliot Z, Neufeld H, Odynski T. Subjective versus objective evaluation of hypnotic efficacy: experience with zolpidem. Sleep 1991;14:399–407.

40. Kuitunen T, Mattila MJ, Seppala T. Actions and interactions of hypnotics on human performance: single doses of zopiclone, triazolam and alcohol. Int Clin Psychopharmacol 1990;5(Suppl 2):115–130.

41. Loscher W, Honack D, Scherkl R, Hashem A, Frey H-H. Pharmacokinetics, anticonvulsant efficacy and adverse effects of the b-carboline abecarnil, a novel ligand for benzodiazepine receptors, after acute and chronic administration in dogs. J Pharmacol Exp Ther 1990;255:541–548.

42. Löscher W, Hönack D. Withdrawal precipitation by benzodiazepine receptor antagonists in dogs chronically treated with diazepam or the novel anxiolytic and anticonvulsant b-carboline abecarnil. Naunyn Schmiedebergs Arch Pharmacol 1992;345:452–460.

43. Lucki I, Volpicelli JR, Schwiezer E. Differential craving between abstinent alcohol-dependent subjects and therapeutic users of benzodiazepines. Proceedings of the Annual Meeting of the Committee on Problems of Drug Dependence, June 1990. Natl Inst Drug Abuse Res Monogr Ser 1991;105:322–323.

44. Maarek L, Cramer P, Attali P, Coquelin JP, Morselli PL. The safety and efficacy of zolpidem in insomniac patients: a long-term open study in general practice. J Int Med Res 1992;20:162–170.

45. Mamelak M, Csima A, Price V. A comparative 25-night sleep laboratory study on the effects of quazepam and triazolam on chronic insomniacs. J Clin Pharmacol 1984;24:65–75.

46. Martin JR, Cumin R, Haefely WE. Precipitated withdrawal in monkeys after repeated daily administration of different benzodiazepines. Soc Neurosci Abstr 1988;14:1109.

47. Martin JR, Kuwahara A, Horii I, Moreau JL, Jenck F, Sepenwall J, Haefley W. Evidence that the benzodiazepine receptor partial agonist RO 16-6028 has minimal abuse and physical dependence liability. Soc Neurosci Abstr 1990;16:1104.

48. Martin WR, Sloan JW, Wala E. Precipitated abstinence in orally dosed benzodiazepine-dependent dogs. J Pharmacol Exp Ther 1990;255:744–755.

49. Massotti M, Schlichting JL, Antonacci MD, Giusti P, Memo M, Costa E, Guidotti A. Gamma-aminobutyric acidA receptor heterogeneity in rat central nervous system: studies with clonazepam and other benzodiazepine ligands. J Pharmacol Exp Ther 1991; 256:1154–1160.

50. Monti JM. Effect of zolpidem on sleep in insomniac patients. Eur J Clin Pharmacol 1989;36(5):461–466.

51. Moreau JL, Jenck F, Pieri L, Schoch P, Martin JR, Haefely WE. Physic al dependence induced in DBA/2J mice by benzodiazepine receptor full agonists, but not by partial agonist Ro 16-6028. Eur J Pharmacol 1990;190:269–273.

52. Morgan K, Oswald I. Anxiety caused by a short-life hypnotic. Br Med J 1982;284:942.

53. Murphy SM, Owen R, Tyrer P. Comparative assessment of efficacy and withdrawal symptoms after 6 and 12 weeks' treatment with diazepam or buspirone. Br J Psychiatry 1989;154:529–534.

54. Nicholson AN, Stone BM. Efficacy of zopiclone in middle age. Sleep 1987;10(Suppl 1):35–39.

55. Perrault G, Morel E, Sanger DJ, Zivkovic B. Lack of tolerance and physical dependence upon repeated treatment with the novel hypnotic zolpidem. J Pharmacol Exp Ther 1992;263:298–303.

56. Praplan-Pahud J, Forster A, Gamulin Z, Tassonyi E, Sauvanet JP. Preoperative sedation before regional anaesthesia: comparison between zolpidem, midazolam and placebo. Br J Anaesth 1990; 64:670–674.

57. Rall TW, Hypnotics and sedatives; ethanol. In: Gilman AG, Rall TW, Nies AS, Taylor P, eds. Goodman and Gilman's: The pharmacological basis of therapeutics, 8th ed. New York: Pergamon Press, 1990;345–382.

58. Rettig HC, de Haan P, Zuurmond WW, von Leeuwen L. Effects of hypnotics on sleep and psychomotor performance. A double-blind randomized study of lormetazepam, midazolam and zopiclone. Anaesthesia 1990;45(12):1079–1082.

59. Rickels K, Schweizer E, Case WG. Benzodiazepines: tolerance and withdrawal: the clinician's point of view. Clin Neuropharmacol 1992;15(Suppl 1, Part A):102A–103A.

60. Roger M, Attali P, Coquelin JP. Multicenter, double-blind, controlled comparison of zolpidem and triazolam in elderly patients with insomnia. Clin Ther 1993;15:127–136.

61. Roth T, Kramer M, Lutz T. Intermediate use of triazolam: a sleep laboratory study. J Int Med Res 1976;4:59–63.

62. Sannerud CA, Ator NA, Griffiths RR. Behavioral pharmacology of abecarnil in baboons: self-injection, drug discrimination and physical dependence. Behavioural Pharmacology 1992;3:507–516.

63. Schlich D, L'Heritier C, Coquelin JP, Attali P. Long-term treatment of insomnia with zolpidem: a multicentre general practitioner study of 107 patients. J Int Med Res 1991;19:271–279.

64. Sellers EM, Kaplan HL, Busto UE. Abuse liability of bretazenil and other partial agonists. Clin Neuropharmacol 1992;15(Suppl):409A.

65. Serra M, Ghiani CA, Foddi MC, Galici R, Motzo C, Biggio G. Failure of flumazenil to precipitate a withdrawal syndrome in cats chronically treated with the new anxioselective b-carboline derivative abecarnil. Behav Pharmacol 1993;4:529–533.

66. Shader RI, Greenblatt DJ. Use of benzodiazepines in anxiety disorders. N Engl J Med 1993;328:1398–1405.

67. Shaw SH, Curson H, Coquelin JP. A double-blind, comparative study of zolpidem and placebo in the treatment of insomnia in elderly psychiatric in-patients. J Int Med Res 1992;20:150–161.

68. Sloan JW, Martin WR, Wala E. Effect of the chronic dose of diazepam on the intensity and characteristics of the precipitated abstinence syndrome in the dog. J Pharmacol Exp Ther 1993;265:1152–1162.

69. Stephens DN, Turski L, Hillman M, Turner JD, Schneider HH, Yamaguchi M. What are the differences between abecarnil and conventional benzodiazepine anxiolytics? Adv Biochem Psychopharmacol 1992;47:395–405.

70. Stephens DN, Turski L, Jones GH, Steppuhn KG, Schneider HH. Abecarnil: a novel anxiolytic with mixed full agonist/partial agonist properties in animal models of anxiety and sedation. In: Anxiolytic b-carbolines: from molecular biology to the clinic. Berlin: Springer-Verlag, 1993;79–95.

71. Steppuhn KG, Schneider HH, Turski L, Stephens DN. Long-term treatment with abecarnil does not induce diazepam-like dependence in mice. J Pharmacol Exp Ther 1993;264:1395–1400.

72. Substance Abuse and Mental Health Services Administration. National household survey on drug abuse: main findings 1991. Revised November 20, 1992. DHHS publication no. (SMA) 93-1980. Washington, DC: U.S. Government Printing Office, 1993.

73. Substance Abuse and Mental Health Services Administration. National household survey on drug abuse: population estimates 1992. DHHS publication no. (SMA) 93-2053. Washington, DC: U.S. Government Printing Office, 1993.

74. Von Voigtlander PF, Lewis RA. A rapid screening method for the assessment of benzodiazepine related-agonist and partial agonist. J Pharmacol Methods 1991;26:1–5.

75. Wieland HA, Luddens H, Seeburg PH. Molecular determinants in GABAA/BZ receptor subtypes. Adv Biochem Psychopharmacol 1992;47:29–40.

76. Woods JH, Katz JL, Winger GD. Abuse liability of benzodiazepines. Pharmacol Rev 1987;39:251–419.

77. Woods JH, Katz JL, Winger GD. Benzodiazepines: use, abuse and consequences. Pharmacol Rev 1992;44:151–347.

78. Woolverton WL, Nader MA, Winger G, Woods JH, Patrick GA, Harris LS. Progress report from the Testing Program for Stimulant and Depressant Drugs 1992. NIDA research monograph, 1994; 132:579–594.

79. Yanagita T, Kato S, Oinuma N. Dependence potential of triazolam tested in rhesus monkeys. CIEA (Cent Inst Exp Anim) Preclin Rep 1983;9:175–186.

80. Yanagita T. Dependence potential of zopiclone tested in monkeys. Pharmacology 1983;27(Suppl 2):216–227.

Back to Chapter

published 2000